FDA plans ultra-fast review of three psychedelic drugs following Trump directive

The FDA will expedite its review of three psychedelic drugs being developed to treat mental health conditions. President Donald Trump signed an executive order directing the FDA to speed research and loosen restrictions on psychedelics. The FDA awarded priority review vouchers to two companies studying psilocybin for depression and a third company studying methylone for post-traumatic stress disorder. The vouchers will shorten the review period from months to weeks. FDA Commissioner Marty Makary stated that the agency owes it to the nation's veterans and Americans suffering from these conditions to evaluate these potential therapies with urgency. The FDA also authorized initial testing of a drug related to ibogaine for people with alcohol use disorder.